Severe infection
Conditions
Interventions
Group A (standard dose) :The first dose of 100mg + 0.9% NaCl 100ml ivgtt, a constant infusion time of 1 hour. After 50 mg + 0.9% NaCl 100 ml q12h ivgtt, a constant infusion time of 1 hour.
Group B (medium dose) :The first dose of 200mg + 0.9% NaCl 200ml ivgtt, a constant infusion time of 1 hour. Then 100 mg + 0.9% NaCl 100 ml ivgtt, a constant infusion time of 1 hour.
Group C (high dose) :The first dose of 200mg + 0.9% NaCl 200ml ivgtt, a constant infusion time of 1 hour. Then 100 mg + 0.9% NaCl 100 ml q12h ivgtt, a constant infusion time of 1 hour.
Sponsors
The Second Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Severe conditions require ICU treatment or have been treated in the ICU. The diagnosis of complex abdominal infections, complex skin and soft tissue infections, and hospital-acquired pneumonia have been treated with broad-spectrum antibiotics for more than 7 days. The infection has not been effectively controlled. Progressive increase; 2. The bacteria cultured were multi-drug resistant, pan-resistant, and fully resistant bacteria (except Pseudomonas aeruginosa and Proteus).
Exclusion criteria
Exclusion criteria: 1. Tigecycline is a non-intravenous patient; 2. Severe liver dysfunction (Child3); 3. Pregnant, lactating women; 4. Patients with sepsis considering a primary disease infection as a urinary tract infection should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tigecycline serum drug concentration;white blood count;bacterial culture;procalcitonin;glutamic-pyruvic transaminase;albumin;Bilirubin;creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| c reactive protein; | — |
Countries
China
Contacts
Public ContactWang Hongliang
The Second Affiliated Hospital of Harbin Medical University
Outcome results
None listed